Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review-Reference-Cited by-同舟云学术

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

Published:2013-11-15 Issue:1 Volume:44 Page:5-16
ISSN:1019-6439
Container-title:International Journal of Oncology
language:en
Short-container-title:

Author:

OH WILLIAM K.,McDERMOTT DAVID,PORTA CAMILLO,LEVY ANTONIN,ELAIDI REZA,SCOTTE FLORIAN,HAWKINS ROBERT,CASTELLANO DANIEL,BELLMUNT JOAQUIM,RHA SUN YOUNG,SUN JONG-MU,NATHAN PAUL,FEINBERG BRUCE A.,SCOTT JEFFREY,McDERMOTT RAY,AHN JIN-HEE,WAGSTAFF JOHN,CHANG YEN-HWA,OU YEN-CHUAN,DONNELLAN PAUL,HUANG CHAO-YUAN,McCAFFREY JOHN,CHIANG PO-HUI,CHUANG CHENG-KENG,KORVES CAROLINE,NEARY MAUREEN P.,DIAZ JOSE R.,MEHMUD FAISAL,DUH MEI SHENG

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis;Frontiers in Pharmacology;2023-09-07

2. Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study;BMC Cancer;2021-01-05

In vivo Screening of Natural Products Against Angiogenesis and Mechanisms of Anti-Angiogenic Activity of Deoxysappanone B 7,4ʹ-Dimethyl Ether

;Drug Design, Development and Therapy;2020-07

4. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up;Japanese Journal of Clinical Oncology;2019-10-21

5. Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study;Japanese Journal of Clinical Oncology;2019-02-22